RATIONALE: Club (Clara) cell protein 16 (CC-16) is a protein that is synthesized predominantly in the lungs and is detectable in serum. Its expression decreases with lung injury and smoking, and is thus a marker of bronchial cell dysfunction. OBJECTIVES: To evaluate the possibility of using serum CC-16 as a biomarker for disease progression in chronic obstructive pulmonary disease (COPD). METHODS: We measured serum CC-16 levels from 4,724 subjects with mild-to-moderate airflow limitation in the Lung Health Study. Using a linear regression model, we determined the relationship of serum CC-16 concentrations to decline in lung function over 9 years. In addition, to determine whether CC-16 plays a major role in the pathogenesis of mild COPD, we exposed CC-16-deficient (-/-) mice to 6 months of cigarette smoke. MEASUREMENTS AND MAIN RESULTS: Reduced serum concentrations of CC-16 were associated with accelerated decline in FEV1 over 9 years (P < 0.0001), and this association persisted after adjustments for age, sex, race, smoking status, airway reactivity, body mass index, and baseline FEV1 (P = 0.0002). However, CC-16(-/-) mice did not demonstrate an enhanced risk of emphysema or small airway remodeling in response to cigarette smoke. CONCLUSIONS: Serum CC-16 is associated with disease progression, and may assist in the identification of "rapid progressors." However, the absence of CC-16 does not appear to modify the risk of cigarette-related COPD in mice.
RATIONALE: Club (Clara) cell protein 16 (CC-16) is a protein that is synthesized predominantly in the lungs and is detectable in serum. Its expression decreases with lung injury and smoking, and is thus a marker of bronchial cell dysfunction. OBJECTIVES: To evaluate the possibility of using serum CC-16 as a biomarker for disease progression in chronic obstructive pulmonary disease (COPD). METHODS: We measured serum CC-16 levels from 4,724 subjects with mild-to-moderate airflow limitation in the Lung Health Study. Using a linear regression model, we determined the relationship of serum CC-16 concentrations to decline in lung function over 9 years. In addition, to determine whether CC-16 plays a major role in the pathogenesis of mild COPD, we exposed CC-16-deficient (-/-) mice to 6 months of cigarette smoke. MEASUREMENTS AND MAIN RESULTS: Reduced serum concentrations of CC-16 were associated with accelerated decline in FEV1 over 9 years (P < 0.0001), and this association persisted after adjustments for age, sex, race, smoking status, airway reactivity, body mass index, and baseline FEV1 (P = 0.0002). However, CC-16(-/-) mice did not demonstrate an enhanced risk of emphysema or small airway remodeling in response to cigarette smoke. CONCLUSIONS: Serum CC-16 is associated with disease progression, and may assist in the identification of "rapid progressors." However, the absence of CC-16 does not appear to modify the risk of cigarette-related COPD in mice.
Authors: Joshua C Snyder; Susan D Reynolds; John W Hollingsworth; Zhuowei Li; Naftali Kaminski; Barry R Stripp Journal: Am J Respir Cell Mol Biol Date: 2009-05-07 Impact factor: 6.914
Authors: S F P Man; L Xing; J E Connett; N R Anthonisen; R A Wise; D P Tashkin; X Zhang; R Vessey; T G Walker; B R Celli; D D Sin Journal: Eur Respir J Date: 2008-09-17 Impact factor: 16.671
Authors: Don D Sin; Bruce E Miller; Annelyse Duvoix; S F Paul Man; Xuekui Zhang; Edwin K Silverman; John E Connett; Nicholas A Anthonisen; Robert A Wise; Donald Tashkin; Bartolome R Celli; Lisa D Edwards; Nicholas Locantore; William Macnee; Ruth Tal-Singer; David A Lomas Journal: Am J Respir Crit Care Med Date: 2011-01-07 Impact factor: 21.405
Authors: Alvar Agusti; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Lisa D Edwards; David A Lomas; William MacNee; Bruce E Miller; Steve Rennard; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Julie C Yates; Jørgen Vestbo Journal: Respir Res Date: 2010-09-10
Authors: Stefano Guerra; Marilyn Halonen; Monica M Vasquez; Amber Spangenberg; Debra A Stern; Wayne J Morgan; Anne L Wright; Iris Lavi; Lluïsa Tarès; Anne-Elie Carsin; Carlota Dobaño; Esther Barreiro; Jan-Paul Zock; Jesús Martínez-Moratalla; Isabel Urrutia; Jordi Sunyer; Dirk Keidel; Medea Imboden; Nicole Probst-Hensch; Jenny Hallberg; Erik Melén; Magnus Wickman; Jean Bousquet; Danielle C M Belgrave; Angela Simpson; Adnan Custovic; Josep M Antó; Fernando D Martinez Journal: Lancet Respir Med Date: 2015-07-06 Impact factor: 30.700
Authors: Nicole P Malvin; Justin T Kern; Ta-Chiang Liu; Steven L Brody; Thaddeus S Stappenbeck Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-05-22 Impact factor: 5.464
Authors: Maria E Laucho-Contreras; Francesca Polverino; Kushagra Gupta; Katherine L Taylor; Emer Kelly; Victor Pinto-Plata; Miguel Divo; Naveed Ashfaq; Hans Petersen; Barry Stripp; Aprile L Pilon; Yohannes Tesfaigzi; Bartolome R Celli; Caroline A Owen Journal: Eur Respir J Date: 2015-02-19 Impact factor: 16.671
Authors: Jing Zhai; Michael Insel; Kenneth J Addison; Debra A Stern; William Pederson; Alane Dy; Joselyn Rojas-Quintero; Caroline A Owen; Duane L Sherrill; Wayne Morgan; Anne L Wright; Marilyn Halonen; Fernando D Martinez; Monica Kraft; Stefano Guerra; Julie G Ledford Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405